glp 1 long term side effects glp-1 long-term cancer Overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds Adverse Effects of GLP-1 Receptor

What is already known on this topic Preclinical studies suggest glucagon-like peptide-1 (GLP-1) receptor agonists act on the mesolimbic reward pathways and reduce drug reinforcement in animal models of alcohol, nicotine, cocaine, and opioid use disorders Observational studies in humans link GLP-1 receptor agonist use to lower risk of incident and recurrent alcohol, tobacco, and cannabis use disorders, but evidence for other substances is lacking Large studies evaluating GLP-1 receptor agonists for preventing substance use disorders (SUDs) or improving hard clinical outcomes in people with established SUDs are lacking What this study adds GLP-1 receptor agonists were associated with lower risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and other SUDs, suggesting potential preventive effects across a broad range of substances In participants with pre-existing SUDs, GLP-1 receptor agonists were associated with reduced risks of SUD related emergency department visits, hospital admissions, and mortality, and drug overdoses and suicidal behaviours Ethics statements Ethical approval This study was approved by the institutional review board of the VA St Louis Health Care System, which granted a waiver of informed consent (protocol No 1606333)

However, most report that these side effects go away after a few days or weeks

Bosch-Traberg, D.Z.I

Their ability to lower HbA1c levels in Type 2 Diabetes (T2D), combined with impressive weightloss benefits, has made them a favorite among both doctors and patients, fueling brand and indication conflation while driving rapid growth and popularity

Additionally, Ozempic offers the added convenience of once-weekly dosing through a simple subcutaneous injection

MNT had the opportunity to speak with Cheng-Han Chen, MD, a board-certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA, about this study